None listed
Conditions
Interventions
None listed
Sponsors
Seoul National University Bundang Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 19 years or older. 2. Patients with intractable upper abdominal pain (VAS = 5) due to upper gastrointestinal malignancies (e.g., pancreatic cancer, biliary tract cancer, gastric cancer). 3. Patients scheduled for bilateral splanchnic nerve block and neurolysis under C-arm guidance for pain management.
Exclusion criteria
Exclusion criteria: 1. History of spinal surgery, congenital anomalies, or severe deformities that make it difficult to identify anatomical landmarks of the T11-12 segments or impossible to perform standard needle placement. 2. Cases where bilateral procedures cannot be performed. 3. History of hypersensitivity or severe allergic reactions to contrast media. 4. Cases requiring emergency procedures or where the patient's condition is unstable, making it difficult to adhere to the research protocol (e.g., repeated imaging). 5. Other cases deemed unsuitable for analysis by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in the cranial-caudal spread range (L-unit) measured on both the left and right sides during the test dose phase | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in the cranial-caudal spread extent (L-unit) measured on both the left and right sides during the mapping phase;Difference in the mediolateral spread width (W-unit) measured on both the left and right sides during the mapping phase;Difference in the mediolateral spread width (W-unit) measured on both the left and right sides during the test dose phase;Change in drug spread: Incremental changes in L-unit and W-unit during the test dose phase compared to the mapping phase;Rate of midline crossing: The proportion of patients in whom the contrast media crossed the midline and spread to the contralateral side during the mapping and test dose phases, respectively;Incidence of asymmetric spread: The proportion of patients in whom drug distribution asymmetry exceeding pre-defined criteria is observed;Pain intensity at 1 month post-procedure (measured using the Brief Pain Inventory);Opioid consumption at 1 month post-procedure;Intensity of breakthrough pain at 1 month post-procedure;Frequency of breakthrough pain at 1 month post-procedure;Physical functional status at 1 month post-procedure (measured by the Eastern Cooperative Oncology Group Performance Status, ECOG-PS);Incidence of procedure-related complications | — |
Countries
Korea, Republic of
Contacts
Public ContactJoon Hee Lee
Seoul National University Bundang Hospital
Outcome results
None listed